Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Vircell Presents Automated Immunoassays and Molecular Diagnostics at MEDICA 2026

By LabMedica International staff writers
Posted on 16 Nov 2026

Vircell (Granada, Spain) is showcasing its portfolio of infectious disease diagnostic solutions at MEDICA 2026, taking place November 16–19 in Düsseldorf, Germany. More...

At Hall 3, Stand A30, the company is highlighting its VirClia Lotus automated chemiluminescence analyzer, VirClia Monotest assays, AMPLIRUN molecular controls, and Virplex real-time PCR kits. These technologies support clinical laboratories in detecting infectious pathogens while providing flexible testing workflows and quality control solutions.

Among the featured products is VirClia Lotus, a fully automated chemiluminescence immunoassay (CLIA) analyzer designed for infectious disease testing. The system supports random-access testing, continuous loading, and priority processing of urgent samples without requiring batch testing. It accommodates up to 50 primary sample tubes and 79 individual tests onboard, processing 40 tests in 90 minutes, with initial results available in approximately 70 minutes. Automated sample identification, quality control, and bidirectional laboratory information system connectivity help streamline laboratory operations.

The analyzer operates with VirClia Monotest assays, which use individual, ready-to-use test strips for detecting infectious disease markers. The portfolio covers more than 90 parameters across respiratory, gastrointestinal, fungal, viral, and sexually transmitted infections, among others. Each monotest incorporates its own quality control, allowing laboratories to perform individual assays without accumulating samples for batch processing.

A featured assay is the Aspergillus galactomannan ag VirClia Monotest which detects Aspergillus galactomannan antigen in serum, plasma, and bronchoalveolar lavage samples to support the diagnosis of invasive aspergillosis. The automated assay provides results in approximately 75 minutes, including sample pretreatment.

Vircell is also presenting its AmpliRun Total molecular controls for monitoring nucleic acid amplification testing. AmpliRun controls contain quantified, purified, and inactivated microbial genetic material for assessing amplification and detection performance across molecular platforms. AmpliRun Total controls incorporate whole inactivated microorganisms in matrices that mimic clinical specimens, enabling laboratories to assess the complete analytical workflow, including nucleic acid extraction and amplification. The controls are available in lyophilized formats to support stability, handling, and transportation.

Completing the exhibit are the Virplex real-time PCR kits for detecting infectious pathogens in human clinical samples. The portfolio includes multiplex assays targeting respiratory, gastrointestinal, sexually transmitted, and other infections. The kits feature lyophilized master mixes, positive controls, and internal controls to monitor amplification performance and potential inhibition. Available in different formats, including predispensed strips and plates, the assays are compatible with commonly used real-time PCR instruments and can be integrated with automated extraction and analysis workflows. Together, these solutions reflect Vircell's focus on combining flexible infectious disease testing with laboratory automation and quality assurance.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Urinalysis Solution
UN-9000
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Researchers developed a blood test that accurately distinguishes early-stage breast cancer from healthy controls and may outperform tissue biopsy in predicting recurrence risk (Image Credit: Adobe Stock)

Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk

Breast cancer screening can reduce mortality, but early detection remains challenging when tumors are small or difficult to identify through imaging. Blood-based liquid biopsies offer a potential complementary... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.